Maynard Um
-
-
-
-
-
-
-
Sarepta Therapeutics (SRPT) PT Raised to $25 at Morgan Stanley
-
-
-
-
-
-
-
BofA Securities on Sarepta Therapeutics (SRPT): sNDAs 'positive first step' but regulatory risk continues
-
-
-
-
-
-
-
Sarepta Therapeutics (SRPT) PT Raised to $25 at Freedom Capital Markets
-
-
-
-
-
-
-
JPMorgan on Sarepta Therapeutics (SRPT): 'Quick Thoughts On Elevidys 3-Year EMBARK Data'
-
-
-
-
-
-
-
Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
-
-
-
-
-
-
-
Sarepta receives FDA approval for ELEVIDYS study with enhanced immunosuppression
-
-
-
-
-
-
-
Mizuho upgrades Sarepta on confidence in Elevidys uptake
-
404,878 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

